WHO vaccine-preventable diseases: monitoring system. 2015 global summary

Last updated 15-Jul-2015 (Data received as of 10-Jul-2015)
Next overall update Fall 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 55'2001 Infant (under 12 months) mortality rate: 62
GDP / capita (US$): 54'6291 Child (under 5 years) mortality rate: 72

Population data in thousands3

  2014  2013  2012  2011  2010  2000  1990  1980 
Total population 322'583  320'051  317'505  314'912  312'247  284'594  254'507  230'176 
Births 4'242  4'230  4'226  4'229  4'236  4'046  4'036  3'484 
Surviving infants 4'217  4'204  4'199  4'202  4'209  4'017  3'997  3'439 
Pop. less than 5 years 20'951  20'785  20'623  20'512  20'441  19'460  19'160  16'685 
Pop. less than 15 years 62'818  62'561  62'301  62'095  61'947  60'760  55'184  52'021 
Female 15-49 years 74'764  74'735  74'740  74'728  74'673  72'685  67'154  59'523 

Number of reported case

(Click for retrospective incidence data for United States of America (the))
Diphtheria
Japanese encephalitis
Measles 187  55  222  63  85  27'786  13'506 
Mumps 584  229  404  2'611  323 
Pertussis 28'532  47'693  18'610  27'410  7'867  4'570  1'730 
Polio*
Rubella 176 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)** 26  37  37  26  35  64  95 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United States of America (the))
Vaccine year result method % card seen                                                
BCG         
DTP1          98  98  99* 
DTP3          94  96  95  95  94  96 
DTP4         
IPV1         
HepB_BD          72  69  64 
HepB3          90  91  92  91  90 
Hib3          93  94  90  88  93 
JapEnc         
MCV1          91  92  92  90  91  86 
MCV2         
PCV1          97  97 
PCV3          92  94  93  92 
Pol3          93  94  93  94  90  95 
Rota1          83  74 
Rota_last          69  44  59  58 
Rubella1          91  92  90 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: Mid July 2016

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United States of America (the))
DTP1 98  98  98  98  98  99  96  98 
DTP3 94  94  96  95  95  94  90  96 
HepB3 90  90  91  92  92  90 
HepB_BD 72  72  69  67  64 
Hib3 93  93  94  90  90  93 
MCV1 91  91  92  92  92  91  90  86 
MCV2
PCV3 92  92  94  93  93 
Pol3 93  93  94  93  93  90  85  95 
Rota_last 69  69  64  59  59 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2014 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 2, 4, 6, >15 months; >4 years; Yes
DTaP 2, 4, 6, > 15 months; > 4 years; Yes
DTaPHepBIPV 2, 4, 6 months; Yes
DTaPHibIPV 2, 4, 6 months;
HPV >11 years (x3 doses); Yes
HepA 12 months; >18 months; Yes
HepB_Adult 18 years; Yes Adults with certain medical conditions, behaviors, travel, or desire to decrease risk of Hepatitis B not vaccinated as a child
HepB_Pediatric st contact; +1, +6 months;
Hib 2, 4, 6, > 12 months; Yes
IPV 2, 4, > 6 months; Yes
MMR 12 months; 4 years; Yes
MenACWY >11, >16 years; Yes
Pneumo_conj 2, 4, 6, >12 months; Yes Also recommended for all adults 65Y and for younger adults with immune compromising conditions
Pneumo_ps 65 years; Yes Also recommended for 18-64Y with certain conditions
Rotavirus 2, 4, 6 months; Yes
Tdap 11 years; Yes Also recommended for adult with no prior Tdap vaccination
Varicella >12 months; 4 years; Yes
Zoster 60 years; Yes

Immunizaton indicators

Indicator Expected answer 2014  2013  2012  2011  2010  2009  2008 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No             
What years does the MYP cover? number     Yes         
Nº of districts with microplans that include activities to raise immunization coverage number              

System performance

Total Nº districts in country number              
Nº districts with DTP3 coverage >=80% number        
% of districts with DTP3 coverage >=80% From 0 to 100%              
Nº districts with measles (MCV1) coverage >=95% number          
% of districts with MCV1 coverage >=95% From 0 to 100%              

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND              
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR     Yes         

Finance

Immunization expenditure financed, using Government funds? From 0 to 100%              

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes      Yes     

Sources

 1  "The 2015 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.